In CLL patients, mutations in BCL-2 are found that can prevent or reduce the binding of venetoclax to the BCL-2 protein, thereby inhibiting its efficacy [121,122,123]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.